EXAS
USDExact Sciences Corporation Common Stock
Reaalajas hind
Hinnagraafik
Põhinäitajad
Turunäitajad
Avatud
$70.070
Kõrge
$72.810
Madal
$67.970
Maht
1.54M
Ettevõtte fundamentaalnäitajad
Turukapitalisatsioon
13.2B
Tööstusharu
Diagnostics & Research
Riik
United States
Kauplemisstatistika
Keskmine maht
2.95M
Börs
NCM
Valuuta
USD
52 nädala vahemik
Seotud uudised
TD Cowen Maintains Buy on Exact Sciences, Raises Price Target to $90
TD Cowen analyst Dan Brennan maintains Exact Sciences with a Buy and raises the price target from $74 to $90.
Baird Maintains Outperform on Exact Sciences, Raises Price Target to $88
Baird analyst Catherine Schulte maintains Exact Sciences with a Outperform and raises the price target from $72 to $88.
Benchmark Maintains Buy on Exact Sciences, Raises Price Target to $75
Benchmark analyst Bruce D. Jackson maintains Exact Sciences with a Buy and raises the price target from $60 to $75.
Guggenheim Maintains Buy on Exact Sciences, Raises Price Target to $75
Guggenheim analyst Subbu Nambi maintains Exact Sciences with a Buy and raises the price target from $70 to $75.
Barclays Maintains Overweight on Exact Sciences, Raises Price Target to $77
Barclays analyst Luke Sergott maintains Exact Sciences with a Overweight and raises the price target from $65 to $77.
Stifel Maintains Buy on Exact Sciences, Raises Price Target to $80
Stifel analyst Daniel Arias maintains Exact Sciences with a Buy and raises the price target from $67 to $80.
Exact Sciences to Participate in November Investor Conference
Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate
Seotud aktsiad
Püsi kursis
Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.